NDAC
This article was originally published in The Tan Sheet
Executive Summary
Meeting tentatively scheduled for Dec. 13-14, although no agenda has been released. NDAC most recently met jointly with Pulmonary-Allergy Drugs Advisory Committee May 11 to consider OTC switch potential of low- and non-sedating antihistamines (1"The Tan Sheet" May 14, p. 3 and 2May 21, pp. 12-14)
You may also be interested in...
FDA, Rx Antihistamine Makers' Next Move: Compromise?
A negotiated compromise between FDA and the manufacturers of second-generation antihistamines seems the most logical way to resolve the legal, regulatory and financial obstacles facing both sides.
Second-Generation Antihistamine OTC Labeling Could Resemble Monograph
OTC labeling for second-generation antihistamines - if the drugs were to switch - may not differ greatly from warnings on existing nonprescription allergic rhinitis symptom relief drugs.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC